| 词条 | Cantuzumab mertansine |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 458291247 | image = Mertansine mab structure.svg | type = mab | mab_type = mab | source = zu/o | target = MUC1 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 400010-39-1 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|changed|FDA}} | UNII = 7Z7EUX7R6M | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | chemical_formula = | molecular_weight = }} Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer.[1] It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1).[2] It was developed by ImmunoGen. MechanismAfter the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.[3] Clinical trialsThree phase I clinical studies had reported results by 2003.[4] By 2005, clinical development had been suspended.[5] See also
References1. ^Statement On A Nonproprietary Name Adopted By The Usan Council - Cantuzumab mertansine, American Medical Association.{{dead link|date=August 2015}} {{Monoclonals for tumors}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^{{cite journal| pmid=18301896 | doi=10.1007/s00280-007-0672-8 | volume=62 | title=Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study | year=2008 | journal=Cancer Chemother Pharmacol | pages=911–9 | last1 = Rodon | first1 = J | last2 = Garrison | first2 = M | last3 = Hammond | first3 = LA | last4 = de Bono | first4 = J | last5 = Smith | first5 = L | last6 = Forero | first6 = L | last7 = Hao | first7 = D | last8 = Takimoto | first8 = C | last9 = Lambert | first9 = JM | last10 = Pandite | first10 = L | last11 = Howard | first11 = M | last12 = Xie | first12 = H | last13 = Tolcher | first13 = AW}} 3. ^A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004 4. ^http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-newsArticle&ID=354351&highlight= 5. ^http://adisinsight.springer.com/drugs/800007546 3 : Antibody-drug conjugates|Monoclonal antibodies for tumors|Experimental cancer drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。